- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT02306161
Kombinationskemoterapi med eller utan Ganitumab vid behandling av patienter med nyligen diagnostiserat metastaserande Ewing-sarkom
Randomiserad fas 3-studie som utvärderar tillägget av den monoklonala antikroppen IGF-1R Ganitumab (AMG 479, NSC# 750008) till multiagent kemoterapi för patienter med nyligen diagnostiserat metastaserande Ewing-sarkom
This randomized phase III trial studies how well combination chemotherapy with or without ganitumab works in treating patients with newly diagnosed Ewing sarcoma that has spread to other parts of the body. Treatment with drugs that block the IGF-1R pathway, such as ganitumab, may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as vincristine, doxorubicin, cyclophosphamide, ifosfamide, and etoposide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether adding ganitumab to combination chemotherapy is more effective in treating patients with newly diagnosed metastatic Ewing sarcoma.
Studieöversikt
Status
Betingelser
Intervention / Behandling
- Läkemedel: Cyclophosphamide
- Läkemedel: Doxorubicin Hydrochloride
- Läkemedel: Doxorubicin
- Läkemedel: Vincristine
- Läkemedel: Vincristine Sulfate
- Läkemedel: Etoposide
- Läkemedel: Etoposide Phosphate
- Strålning: External Beam Radiation Therapy
- Läkemedel: Ifosfamide
- Strålning: Stereotactic Radiosurgery
- Procedur: Therapeutic Surgical Procedure
- Biologisk: Ganitumab
Detaljerad beskrivning
PRIMARY OBJECTIVES:
I. To determine if event-free survival (EFS) in patients with newly diagnosed metastatic Ewing sarcoma treated with multiagent chemotherapy is improved with the addition of ganitumab (AMG 479).
SECONDARY OBJECTIVES:
I. To describe the toxicity of the addition of ganitumab to multimodality therapy for patients with newly diagnosed metastatic Ewing sarcoma.
II. To compare overall survival in patients with newly diagnosed metastatic Ewing sarcoma treated with multiagent chemotherapy with and without the addition of ganitumab.
EXPLORATORY OBJECTIVES:
I. To compare bone marrow response rates in patients with newly diagnosed metastatic Ewing sarcoma treated with multiagent chemotherapy with and without the addition of ganitumab.
II. To describe the toxicity of 6 months of ganitumab monotherapy as maintenance therapy following multimodality therapy in patients with newly diagnosed metastatic Ewing sarcoma.
III. To describe trough levels of ganitumab in a cohort of patients with Ewing sarcoma < 21 years of age treated with 18 mg/kg.
IV. To describe the feasibility of and local failure rates following hypofractionated stereotactic body radiotherapy (SBRT) directed at bone metastases in patients with newly diagnosed metastatic Ewing sarcoma.
V. To determine if EFS, overall survival, bone marrow response rates, and toxicity differ based on serum markers of the insulin-like growth factor 1 (IGF-1) pathway in patients with newly diagnosed metastatic Ewing sarcoma treated with interval compressed chemotherapy with and without the addition of ganitumab.
VI. To determine if EFS, overall survival, and bone marrow response rates differ based on protein, deoxyribose nucleic acid (DNA), and ribonucleic acid (RNA) marker in patients with newly diagnosed metastatic Ewing sarcoma treated with interval compressed chemotherapy with and without the addition of ganitumab.
VII. To evaluate bone marrow micrometastatic disease and tumor cell surface IGF-1R expression at diagnosis and after 3 and 6 cycles of study therapy in patients with newly diagnosed metastatic Ewing sarcoma.
VIII. To determine if the presence of germline polymorphisms in EGFR correlate with response to multiagent therapy with and without ganitumab.
IX. To investigate the ability of fludeoxyglucose F 18-positron emission tomography (FDG-PET) to augment conventional response assessment of primary Ewing sarcoma tumors by magnetic resonance imaging (MRI).
X. To explore FDG-PET response at the primary tumor as a prognostic marker and as a predictive biomarker of clinical activity of IGF-1R inhibition in patients with newly diagnosed metastatic Ewing sarcoma.
XI. To collect data on institutional testing for Ewing sarcoma breakpoint region 1 (EWSR1) translocation status in patients enrolling on study.
XII. To explore the capacity of plasma cell-free DNA analysis to detect tumor-specific genetic changes at initial diagnosis and after initiation of protocol therapy.
XIII. To collect a population of bone marrow metastatic tumor cells by flow cytometry for genomic profiling.
OUTLINE: Patients are randomized to 1 of 2 treatment regimens. (As of 3/20/2019, the study is closed to accrual and patients in Regimen B no longer receive ganitumab.)
REGIMEN A (vincristine sulfate, doxorubicin hydrochloride and cyclophosphamide [VDC] and ifosfamide and etoposide phosphate [IE]):
INDUCTION THERAPY: Patients receive vincristine sulfate intravenously (IV) over 1 minute on day 1, doxorubicin hydrochloride IV over 1-15 minutes on days 1 and 2, and cyclophosphamide IV over 30-60 minutes on day 1 of weeks 1, 5, and 9, and ifosfamide IV over 1 hour on days 1 to 5 and etoposide phosphate IV over 1-2 hours on days 1 to 5 of weeks 3, 7, and 11.
LOCAL CONTROL THERAPY: Between weeks 13-18, patients undergo surgery and/or radiation therapy.
CONSOLIDATION THERAPY: Patients receive vincristine sulfate IV over 1 minute on day 1 of weeks 1, 7, 9, and 13; doxorubicin hydrochloride IV over 1-15 minutes on days 1 and 2 of weeks 1 and 7, cyclophosphamide IV over 30-60 minutes on day 1 of weeks 1, 7, 9, and 13, ifosfamide IV over 1 hour on days 1 to 5 of weeks 3, 5, 11, and 15, and etoposide phosphate IV over 1-2 hours on days 1 to 5 of weeks 3, 5, 11, and 15.
METASTATIC SITE IRRADIATION: Patients with lung metastases undergo whole lung radiation and patients with bone metastases undergo definitive SBRT or external beam radiation therapy (EBRT).
REGIMEN B (VDC/IE + ganitumab):
INDUCTION THERAPY: Patients receive Induction therapy as in Regimen A and receive ganitumab IV over 30-60 minutes or 60-120 minutes on day 1 of weeks 1, 3, 5, 7, 9, and 11.
LOCAL CONTROL THERAPY: Between weeks 13-18, patients undergo surgery and/or radiation therapy.
CONSOLIDATION THERAPY: Patients receive Consolidation therapy as in Regimen A and receive ganitumab IV over 30-60 minutes or 60-120 minutes on day 1 of weeks 7, 9, 11, 13, and 15.
METASTATIC SITE IRRADIATION: Patients with lung metastases undergo whole lung radiation and patients with bone metastases undergo definitive SBRT or EBRT.
MAINTENANCE: Patients receive ganitumab IV over 30-60 minutes or 60-120 minutes every 3 weeks for 8 cycles.
After completion of study treatment, patients are followed for 10 years.
Studietyp
Inskrivning (Faktisk)
Fas
- Fas 3
Kontakter och platser
Studieorter
-
-
Alabama
-
Birmingham, Alabama, Förenta staterna, 35233
- Children's Hospital of Alabama
-
Mobile, Alabama, Förenta staterna, 36604
- USA Health Strada Patient Care Center
-
-
Alaska
-
Anchorage, Alaska, Förenta staterna, 99508
- Providence Alaska Medical Center
-
-
Arizona
-
Mesa, Arizona, Förenta staterna, 85202
- Banner Children's at Desert
-
Phoenix, Arizona, Förenta staterna, 85016
- Phoenix Childrens Hospital
-
Tucson, Arizona, Förenta staterna, 85719
- Banner University Medical Center - Tucson
-
Yuma, Arizona, Förenta staterna, 85364
- Onvida Health Yuma Medical Center
-
-
Arkansas
-
Hot Springs, Arkansas, Förenta staterna, 71913
- CHI Saint Vincent Cancer Center Hot Springs
-
Little Rock, Arkansas, Förenta staterna, 72202-3591
- Arkansas Children's Hospital
-
-
California
-
Downey, California, Förenta staterna, 90242
- Kaiser Permanente Downey Medical Center
-
Duarte, California, Förenta staterna, 91010
- City of Hope Comprehensive Cancer Center
-
Loma Linda, California, Förenta staterna, 92354
- Loma Linda University Medical Center
-
Long Beach, California, Förenta staterna, 90806
- Miller Children's and Women's Hospital Long Beach
-
Los Angeles, California, Förenta staterna, 90027
- Children's Hospital Los Angeles
-
Madera, California, Förenta staterna, 93636
- Valley Children's Hospital
-
Oakland, California, Förenta staterna, 94609
- UCSF Benioff Children's Hospital Oakland
-
Oakland, California, Förenta staterna, 94611
- Kaiser Permanente-Oakland
-
Orange, California, Förenta staterna, 92868
- Children's Hospital of Orange County
-
Palo Alto, California, Förenta staterna, 94304
- Lucile Packard Children's Hospital Stanford University
-
Sacramento, California, Förenta staterna, 95816
- Sutter Medical Center Sacramento
-
Sacramento, California, Förenta staterna, 95817
- University of California Davis Comprehensive Cancer Center
-
San Diego, California, Förenta staterna, 92123
- Rady Children's Hospital - San Diego
-
San Francisco, California, Förenta staterna, 94158
- UCSF Medical Center-Mission Bay
-
San Francisco, California, Förenta staterna, 94143
- UCSF Medical Center-Parnassus
-
Torrance, California, Förenta staterna, 90502
- Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
-
-
Colorado
-
Aurora, Colorado, Förenta staterna, 80045
- Children's Hospital Colorado
-
Colorado Springs, Colorado, Förenta staterna, 80907
- Penrose-Saint Francis Healthcare
-
Colorado Springs, Colorado, Förenta staterna, 80907
- Rocky Mountain Cancer Centers-Penrose
-
Denver, Colorado, Förenta staterna, 80218
- Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center
-
Denver, Colorado, Förenta staterna, 80210
- AdventHealth Porter
-
Durango, Colorado, Förenta staterna, 81301
- Mercy Medical Center
-
Durango, Colorado, Förenta staterna, 81301
- CommonSpirit Cancer Center Mercy
-
Golden, Colorado, Förenta staterna, 80401
- Mountain Blue Cancer Care Center
-
Lakewood, Colorado, Förenta staterna, 80228
- Rocky Mountain Cancer Centers-Lakewood
-
Lakewood, Colorado, Förenta staterna, 80228
- CommonSpirit Saint Anthony Hospital Cancer Center
-
Littleton, Colorado, Förenta staterna, 80122
- AdventHealth Littleton
-
Longmont, Colorado, Förenta staterna, 80501
- Longmont United Hospital
-
Longmont, Colorado, Förenta staterna, 80501
- Rocky Mountain Cancer Centers-Longmont
-
Parker, Colorado, Förenta staterna, 80138
- Rocky Mountain Cancer Centers-Parker
-
Parker, Colorado, Förenta staterna, 80138
- AdventHealth Parker
-
Pueblo, Colorado, Förenta staterna, 81004
- Saint Mary Corwin Medical Center
-
Pueblo, Colorado, Förenta staterna, 81008
- Rocky Mountain Cancer Centers - Pueblo
-
Thornton, Colorado, Förenta staterna, 80260
- Rocky Mountain Cancer Centers-Thornton
-
-
Connecticut
-
Hartford, Connecticut, Förenta staterna, 06106
- Connecticut Children's Medical Center
-
New Haven, Connecticut, Förenta staterna, 06520
- Yale University
-
-
Delaware
-
Wilmington, Delaware, Förenta staterna, 19803
- Alfred I duPont Hospital for Children
-
-
District of Columbia
-
Washington D.C., District of Columbia, Förenta staterna, 20010
- Children's National Medical Center
-
Washington D.C., District of Columbia, Förenta staterna, 20007
- MedStar Georgetown University Hospital
-
-
Florida
-
Fort Myers, Florida, Förenta staterna, 33908
- Golisano Children's Hospital of Southwest Florida
-
Gainesville, Florida, Förenta staterna, 32610
- UF Health Cancer Institute - Gainesville
-
Hollywood, Florida, Förenta staterna, 33021
- Memorial Regional Hospital/Joe DiMaggio Children's Hospital
-
Jacksonville, Florida, Förenta staterna, 32207
- Nemours Children's Clinic-Jacksonville
-
Miami, Florida, Förenta staterna, 33155
- Nicklaus Children's Hospital
-
Miami, Florida, Förenta staterna, 33136
- University of Miami Miller School of Medicine-Sylvester Cancer Center
-
Orlando, Florida, Förenta staterna, 32827
- Nemours Children's Hospital
-
Orlando, Florida, Förenta staterna, 32803
- AdventHealth Orlando
-
Orlando, Florida, Förenta staterna, 32806
- Arnold Palmer Hospital for Children
-
Pensacola, Florida, Förenta staterna, 32504
- Nemours Children's Clinic - Pensacola
-
St. Petersburg, Florida, Förenta staterna, 33701
- Johns Hopkins All Children's Hospital
-
Tampa, Florida, Förenta staterna, 33607
- Saint Joseph's Hospital/Children's Hospital-Tampa
-
West Palm Beach, Florida, Förenta staterna, 33407
- Saint Mary's Medical Center
-
-
Georgia
-
Atlanta, Georgia, Förenta staterna, 30329
- Children's Healthcare of Atlanta - Arthur M Blank Hospital
-
Augusta, Georgia, Förenta staterna, 30912
- Augusta University Medical Center
-
Savannah, Georgia, Förenta staterna, 31404
- Memorial Health University Medical Center
-
-
Hawaii
-
Honolulu, Hawaii, Förenta staterna, 96813
- Straub Clinic and Hospital
-
Honolulu, Hawaii, Förenta staterna, 96826
- Kapiolani Medical Center for Women and Children
-
Honolulu, Hawaii, Förenta staterna, 96819
- Kaiser Permanente Moanalua Medical Center
-
-
Idaho
-
Boise, Idaho, Förenta staterna, 83712
- Saint Luke's Cancer Institute - Boise
-
-
Illinois
-
Aurora, Illinois, Förenta staterna, 60504
- Rush-Copley Medical Center
-
Chicago, Illinois, Förenta staterna, 60637
- University of Chicago Comprehensive Cancer Center
-
Chicago, Illinois, Förenta staterna, 60612
- University of Illinois
-
Chicago, Illinois, Förenta staterna, 60611
- Lurie Children's Hospital-Chicago
-
Danville, Illinois, Förenta staterna, 61832
- Carle at The Riverfront
-
Effingham, Illinois, Förenta staterna, 62401
- Carle Physician Group-Effingham
-
Mattoon, Illinois, Förenta staterna, 61938
- Carle Physician Group-Mattoon/Charleston
-
Maywood, Illinois, Förenta staterna, 60153
- Loyola University Medical Center
-
Mount Vernon, Illinois, Förenta staterna, 62864
- SSM Health Good Samaritan
-
Oak Lawn, Illinois, Förenta staterna, 60453
- Advocate Children's Hospital-Oak Lawn
-
Park Ridge, Illinois, Förenta staterna, 60068
- Advocate Children's Hospital-Park Ridge
-
Peoria, Illinois, Förenta staterna, 61637
- OSF Children's Hospital of Illinois
-
Springfield, Illinois, Förenta staterna, 62702
- Southern Illinois University School of Medicine
-
Springfield, Illinois, Förenta staterna, 62702
- Saint John's Hospital
-
Springfield, Illinois, Förenta staterna, 62781
- Springfield Memorial Hospital
-
Urbana, Illinois, Förenta staterna, 61801
- Carle Cancer Center
-
Urbana, Illinois, Förenta staterna, 61801
- The Carle Foundation Hospital
-
Yorkville, Illinois, Förenta staterna, 60560
- Rush-Copley Healthcare Center
-
-
Indiana
-
Evansville, Indiana, Förenta staterna, 47713
- Deaconess Clinic Downtown
-
Indianapolis, Indiana, Förenta staterna, 46202
- Riley Hospital for Children
-
Indianapolis, Indiana, Förenta staterna, 46260
- Ascension Saint Vincent Indianapolis Hospital
-
Michigan City, Indiana, Förenta staterna, 46360
- Franciscan Saint Anthony Health-Michigan City
-
Michigan City, Indiana, Förenta staterna, 46360
- Woodland Cancer Care Center
-
Newburgh, Indiana, Förenta staterna, 47630
- Chancellor Center for Oncology
-
-
Iowa
-
Clive, Iowa, Förenta staterna, 50325
- Mercy Cancer Center-West Lakes
-
Clive, Iowa, Förenta staterna, 50325
- UI Health Care Mission Cancer and Blood - West Des Moines Clinic
-
Council Bluffs, Iowa, Förenta staterna, 51503
- Alegent Health Mercy Hospital
-
Creston, Iowa, Förenta staterna, 50801
- Greater Regional Medical Center
-
Des Moines, Iowa, Förenta staterna, 50314
- Mercy Medical Center - Des Moines
-
Des Moines, Iowa, Förenta staterna, 50309
- Blank Children's Hospital
-
Des Moines, Iowa, Förenta staterna, 50314
- UI Health Care Mission Cancer and Blood - Laurel Clinic
-
Iowa City, Iowa, Förenta staterna, 52242
- University of Iowa/Holden Comprehensive Cancer Center
-
West Des Moines, Iowa, Förenta staterna, 50266
- Mercy Medical Center-West Lakes
-
-
Kentucky
-
Bardstown, Kentucky, Förenta staterna, 40004
- CommonSpirit Saint Joseph Hospital - Bardstown
-
Corbin, Kentucky, Förenta staterna, 40701
- Commonwealth Cancer Center-Corbin
-
Lexington, Kentucky, Förenta staterna, 40536
- University of Kentucky/Markey Cancer Center
-
Lexington, Kentucky, Förenta staterna, 40504
- Saint Joseph Radiation Oncology Resource Center
-
Lexington, Kentucky, Förenta staterna, 40509
- CommonSpirit Saint Joseph Medical Center - East Lexington
-
London, Kentucky, Förenta staterna, 40741
- CommonSpirit Saint Joseph Hospital London
-
Louisville, Kentucky, Förenta staterna, 40202
- Jewish Hospital
-
Louisville, Kentucky, Förenta staterna, 40202
- Norton Children's Hospital
-
Louisville, Kentucky, Förenta staterna, 40245
- UofL Health Medical Center Northeast
-
Louisville, Kentucky, Förenta staterna, 40215
- Saints Mary and Elizabeth Hospital
-
Shepherdsville, Kentucky, Förenta staterna, 40165
- Jewish Hospital Medical Center South
-
-
Louisiana
-
New Orleans, Louisiana, Förenta staterna, 70121
- Ochsner Medical Center Jefferson
-
New Orleans, Louisiana, Förenta staterna, 70118
- Children's Hospital New Orleans
-
-
Maine
-
Bangor, Maine, Förenta staterna, 04401
- Eastern Maine Medical Center
-
Scarborough, Maine, Förenta staterna, 04074
- Maine Children's Cancer Program
-
-
Maryland
-
Baltimore, Maryland, Förenta staterna, 21287
- Johns Hopkins University/Sidney Kimmel Cancer Center
-
Baltimore, Maryland, Förenta staterna, 21215
- Sinai Hospital of Baltimore
-
Baltimore, Maryland, Förenta staterna, 21201
- University of Maryland/Greenebaum Cancer Center
-
Bethesda, Maryland, Förenta staterna, 20889-5600
- Walter Reed National Military Medical Center
-
-
Massachusetts
-
Boston, Massachusetts, Förenta staterna, 02215
- Dana-Farber Cancer Institute
-
Boston, Massachusetts, Förenta staterna, 02114
- Massachusetts General Hospital Cancer Center
-
Springfield, Massachusetts, Förenta staterna, 01199
- Baystate Medical Center
-
Worcester, Massachusetts, Förenta staterna, 01655
- UMass Memorial Medical Center - University Campus
-
-
Michigan
-
Ann Arbor, Michigan, Förenta staterna, 48109
- C S Mott Children's Hospital
-
Ann Arbor, Michigan, Förenta staterna, 48109
- University of Michigan Rogel Cancer Center
-
Battle Creek, Michigan, Förenta staterna, 49017
- Bronson Battle Creek
-
Detroit, Michigan, Förenta staterna, 48201
- Wayne State University/Karmanos Cancer Institute
-
Detroit, Michigan, Förenta staterna, 48236
- Henry Ford Health Saint John Hospital
-
Flint, Michigan, Förenta staterna, 48503
- Hurley Medical Center
-
Grand Rapids, Michigan, Förenta staterna, 49503
- Trinity Health Grand Rapids Hospital
-
Grand Rapids, Michigan, Förenta staterna, 49503
- Corewell Health Grand Rapids Hospitals - Butterworth Hospital
-
Grand Rapids, Michigan, Förenta staterna, 49503
- Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital
-
Kalamazoo, Michigan, Förenta staterna, 49007
- West Michigan Cancer Center
-
Kalamazoo, Michigan, Förenta staterna, 49007
- Bronson Methodist Hospital
-
Kalamazoo, Michigan, Förenta staterna, 49048
- Beacon Kalamazoo
-
Muskegon, Michigan, Förenta staterna, 49444
- Trinity Health Muskegon Hospital
-
Niles, Michigan, Förenta staterna, 49120
- Corewell Health Lakeland Hospitals - Niles Hospital
-
Port Huron, Michigan, Förenta staterna, 48060
- Lake Huron Medical Center
-
Port Huron, Michigan, Förenta staterna, 48060
- Huron Medical Center PC
-
Reed City, Michigan, Förenta staterna, 49677
- Corewell Health Reed City Hospital
-
Royal Oak, Michigan, Förenta staterna, 48073
- Corewell Health Children's
-
Saint Joseph, Michigan, Förenta staterna, 49085
- Corewell Health Lakeland Hospitals - Marie Yeager Cancer Center
-
Saint Joseph, Michigan, Förenta staterna, 49085
- Corewell Health Lakeland Hospitals - Saint Joseph Hospital
-
Traverse City, Michigan, Förenta staterna, 49684
- Munson Medical Center
-
-
Minnesota
-
Duluth, Minnesota, Förenta staterna, 55805
- Essentia Health Cancer Center
-
Minneapolis, Minnesota, Förenta staterna, 55404
- Children's Hospitals and Clinics of Minnesota - Minneapolis
-
Minneapolis, Minnesota, Förenta staterna, 55455
- University of Minnesota/Masonic Cancer Center
-
Rochester, Minnesota, Förenta staterna, 55905
- Mayo Clinic in Rochester
-
-
Mississippi
-
Jackson, Mississippi, Förenta staterna, 39216
- University of Mississippi Medical Center
-
-
Missouri
-
Bolivar, Missouri, Förenta staterna, 65613
- Central Care Cancer Center - Bolivar
-
Branson, Missouri, Förenta staterna, 65616
- Cox Cancer Center Branson
-
Columbia, Missouri, Förenta staterna, 65212
- University of Missouri Children's Hospital
-
Joplin, Missouri, Förenta staterna, 64804
- Freeman Health System
-
Joplin, Missouri, Förenta staterna, 64804
- Mercy Hospital Joplin
-
Kansas City, Missouri, Förenta staterna, 64108
- Children's Mercy Hospitals and Clinics
-
Rolla, Missouri, Förenta staterna, 65401
- Mercy Clinic-Rolla-Cancer and Hematology
-
Rolla, Missouri, Förenta staterna, 65401
- Phelps Health Delbert Day Cancer Institute
-
Saint Joseph, Missouri, Förenta staterna, 64506
- Heartland Regional Medical Center
-
Springfield, Missouri, Förenta staterna, 65807
- CoxHealth South Hospital
-
Springfield, Missouri, Förenta staterna, 65804
- Mercy Hospital Springfield
-
St Louis, Missouri, Förenta staterna, 63110
- Washington University School of Medicine
-
St Louis, Missouri, Förenta staterna, 63109
- Mercy Infusion Center - Chippewa
-
St Louis, Missouri, Förenta staterna, 63141
- Mercy Hospital Saint Louis
-
St Louis, Missouri, Förenta staterna, 63104
- Cardinal Glennon Children's Medical Center
-
-
Nebraska
-
Bellevue, Nebraska, Förenta staterna, 68123
- Nebraska Medicine-Bellevue
-
Grand Island, Nebraska, Förenta staterna, 68803
- Nebraska Cancer Specialists/Oncology Hematology West PC
-
Kearney, Nebraska, Förenta staterna, 68847
- CHI Health Good Samaritan
-
Kearney, Nebraska, Förenta staterna, 68845
- Fred and Pamela Buffett Cancer Center - Kearney
-
Lincoln, Nebraska, Förenta staterna, 68510
- Saint Elizabeth Regional Medical Center
-
Omaha, Nebraska, Förenta staterna, 68198
- University of Nebraska Medical Center
-
Omaha, Nebraska, Förenta staterna, 68124
- Alegent Health Bergan Mercy Medical Center
-
Omaha, Nebraska, Förenta staterna, 68118
- Nebraska Medicine-Village Pointe
-
Omaha, Nebraska, Förenta staterna, 68122
- Alegent Health Immanuel Medical Center
-
Omaha, Nebraska, Förenta staterna, 68130
- Alegent Health Lakeside Hospital
-
Omaha, Nebraska, Förenta staterna, 68114
- Children's Hospital and Medical Center of Omaha
-
Omaha, Nebraska, Förenta staterna, 68122
- Hematology and Oncology Consultants PC
-
Papillion, Nebraska, Förenta staterna, 68046
- Midlands Community Hospital
-
-
Nevada
-
Carson City, Nevada, Förenta staterna, 89703
- Carson Tahoe Regional Medical Center
-
Henderson, Nevada, Förenta staterna, 89052
- Comprehensive Cancer Centers of Nevada-Horizon Ridge
-
Las Vegas, Nevada, Förenta staterna, 89144
- Summerlin Hospital Medical Center
-
Las Vegas, Nevada, Förenta staterna, 89109
- Sunrise Hospital and Medical Center
-
Las Vegas, Nevada, Förenta staterna, 89135
- Alliance for Childhood Diseases/Cure 4 the Kids Foundation
-
Las Vegas, Nevada, Förenta staterna, 89102
- University Medical Center of Southern Nevada
-
Las Vegas, Nevada, Förenta staterna, 89128
- Ann M Wierman MD LTD
-
Pahrump, Nevada, Förenta staterna, 89048
- Hope Cancer Care of Nevada-Pahrump
-
Reno, Nevada, Förenta staterna, 89502
- Renown Regional Medical Center
-
Reno, Nevada, Förenta staterna, 89503
- Saint Mary's Regional Medical Center
-
Reno, Nevada, Förenta staterna, 89509
- Radiation Oncology Associates
-
-
New Hampshire
-
Lebanon, New Hampshire, Förenta staterna, 03756
- Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center
-
-
New Jersey
-
Hackensack, New Jersey, Förenta staterna, 07601
- Hackensack University Medical Center
-
Morristown, New Jersey, Förenta staterna, 07960
- Morristown Medical Center
-
New Brunswick, New Jersey, Förenta staterna, 08901
- Saint Peter's University Hospital
-
New Brunswick, New Jersey, Förenta staterna, 08903
- Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital
-
Newark, New Jersey, Förenta staterna, 07112
- Newark Beth Israel Medical Center
-
Paterson, New Jersey, Förenta staterna, 07503
- Saint Joseph's Regional Medical Center
-
-
New York
-
Albany, New York, Förenta staterna, 12208
- Albany Medical Center
-
Buffalo, New York, Förenta staterna, 14263
- Roswell Park Cancer Institute
-
Glens Falls, New York, Förenta staterna, 12801
- Glens Falls Hospital
-
Mineola, New York, Förenta staterna, 11501
- NYU Langone Hospital - Long Island
-
New Hyde Park, New York, Förenta staterna, 11040
- The Steven and Alexandra Cohen Children's Medical Center of New York
-
New York, New York, Förenta staterna, 10029
- Mount Sinai Hospital
-
New York, New York, Förenta staterna, 10032
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
-
New York, New York, Förenta staterna, 10016
- Laura and Isaac Perlmutter Cancer Center at NYU Langone
-
Rochester, New York, Förenta staterna, 14642
- University of Rochester
-
Stony Brook, New York, Förenta staterna, 11794
- Stony Brook University Medical Center
-
Syracuse, New York, Förenta staterna, 13210
- State University of New York Upstate Medical University
-
The Bronx, New York, Förenta staterna, 10461
- Montefiore Medical Center-Einstein Campus
-
The Bronx, New York, Förenta staterna, 10467
- Children's Hospital at Montefiore
-
The Bronx, New York, Förenta staterna, 10467
- Montefiore Medical Center - Moses Campus
-
The Bronx, New York, Förenta staterna, 10461
- Montefiore Medical Center-Weiler Hospital
-
Valhalla, New York, Förenta staterna, 10595
- New York Medical College
-
-
North Carolina
-
Asheville, North Carolina, Förenta staterna, 28801
- Mission Hospital
-
Chapel Hill, North Carolina, Förenta staterna, 27599
- UNC Lineberger Comprehensive Cancer Center
-
Charlotte, North Carolina, Förenta staterna, 28203
- Carolinas Medical Center/Levine Cancer Institute
-
Durham, North Carolina, Förenta staterna, 27710
- Duke University Medical Center
-
Winston-Salem, North Carolina, Förenta staterna, 27157
- Wake Forest University Health Sciences
-
-
North Dakota
-
Fargo, North Dakota, Förenta staterna, 58122
- Sanford Broadway Medical Center
-
-
Ohio
-
Akron, Ohio, Förenta staterna, 44308
- Children's Hospital Medical Center of Akron
-
Cincinnati, Ohio, Förenta staterna, 45229
- Cincinnati Children's Hospital Medical Center
-
Cincinnati, Ohio, Förenta staterna, 45220
- Good Samaritan Hospital - Cincinnati
-
Cincinnati, Ohio, Förenta staterna, 45242
- Bethesda North Hospital
-
Cincinnati, Ohio, Förenta staterna, 45247
- TriHealth Cancer Institute-Westside
-
Cincinnati, Ohio, Förenta staterna, 45255
- TriHealth Cancer Institute-Anderson
-
Cleveland, Ohio, Förenta staterna, 44195
- Cleveland Clinic Foundation
-
Cleveland, Ohio, Förenta staterna, 44106
- Rainbow Babies and Childrens Hospital
-
Columbus, Ohio, Förenta staterna, 43205
- Nationwide Children's Hospital
-
Dayton, Ohio, Förenta staterna, 45404
- Dayton Children's Hospital
-
Toledo, Ohio, Förenta staterna, 43606
- ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Förenta staterna, 73104
- University of Oklahoma Health Sciences Center
-
Oklahoma City, Oklahoma, Förenta staterna, 73120
- Mercy Hospital Oklahoma City
-
-
Oregon
-
Portland, Oregon, Förenta staterna, 97239
- Oregon Health and Science University
-
Portland, Oregon, Förenta staterna, 97227
- Legacy Emanuel Children's Hospital
-
-
Pennsylvania
-
Allentown, Pennsylvania, Förenta staterna, 18103
- Lehigh Valley Hospital-Cedar Crest
-
Bethlehem, Pennsylvania, Förenta staterna, 18017
- Lehigh Valley Hospital - Muhlenberg
-
Danville, Pennsylvania, Förenta staterna, 17822
- Geisinger Medical Center
-
Hershey, Pennsylvania, Förenta staterna, 17033
- Penn State Children's Hospital
-
Philadelphia, Pennsylvania, Förenta staterna, 19104
- Children's Hospital of Philadelphia
-
Philadelphia, Pennsylvania, Förenta staterna, 19134
- Saint Christopher's Hospital for Children
-
Philadelphia, Pennsylvania, Förenta staterna, 19102
- Drexel University School of Medicine
-
Pittsburgh, Pennsylvania, Förenta staterna, 15224
- Children's Hospital of Pittsburgh of UPMC
-
-
Rhode Island
-
Providence, Rhode Island, Förenta staterna, 02903
- Rhode Island Hospital
-
-
South Carolina
-
Charleston, South Carolina, Förenta staterna, 29425
- Medical University of South Carolina
-
Columbia, South Carolina, Förenta staterna, 29203
- Prisma Health Richland Hospital
-
Greenville, South Carolina, Förenta staterna, 29607
- Saint Francis Cancer Center
-
Greenville, South Carolina, Förenta staterna, 29601
- Saint Francis Hospital
-
Greenville, South Carolina, Förenta staterna, 29605
- BI-LO Charities Children's Cancer Center
-
-
South Dakota
-
Sioux Falls, South Dakota, Förenta staterna, 57117-5134
- Sanford USD Medical Center - Sioux Falls
-
-
Tennessee
-
Chattanooga, Tennessee, Förenta staterna, 37403
- T C Thompson Children's Hospital
-
Chattanooga, Tennessee, Förenta staterna, 37404
- Memorial Hospital
-
Hixson, Tennessee, Förenta staterna, 37343
- Pulmonary Medicine Center of Chattanooga-Hixson
-
Knoxville, Tennessee, Förenta staterna, 37916
- East Tennessee Childrens Hospital
-
Memphis, Tennessee, Förenta staterna, 38105
- Saint Jude Children's Research Hospital
-
Nashville, Tennessee, Förenta staterna, 37232
- Vanderbilt University/Ingram Cancer Center
-
Nashville, Tennessee, Förenta staterna, 37203
- The Children's Hospital at TriStar Centennial
-
Ooltewah, Tennessee, Förenta staterna, 37363
- Memorial GYN Plus
-
-
Texas
-
Austin, Texas, Förenta staterna, 78723
- Dell Children's Medical Center of Central Texas
-
Bryan, Texas, Förenta staterna, 77802
- Saint Joseph Regional Cancer Center
-
Corpus Christi, Texas, Förenta staterna, 78411
- Driscoll Children's Hospital
-
Dallas, Texas, Förenta staterna, 75390
- UT Southwestern/Simmons Cancer Center-Dallas
-
Dallas, Texas, Förenta staterna, 75230
- Medical City Dallas Hospital
-
El Paso, Texas, Förenta staterna, 79905
- El Paso Children's Hospital
-
Fort Worth, Texas, Förenta staterna, 76104
- Cook Children's Medical Center
-
Houston, Texas, Förenta staterna, 77030
- UT MD Anderson Cancer Center
-
Houston, Texas, Förenta staterna, 77030
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center
-
Lubbock, Texas, Förenta staterna, 79410
- Covenant Children's Hospital
-
Lubbock, Texas, Förenta staterna, 79415
- UMC Cancer Center / UMC Health System
-
Lubbock, Texas, Förenta staterna, 79430
- Texas Tech University Health Sciences Center-Lubbock
-
San Antonio, Texas, Förenta staterna, 78229
- University of Texas Health Science Center at San Antonio
-
San Antonio, Texas, Förenta staterna, 78207
- Children's Hospital of San Antonio
-
San Antonio, Texas, Förenta staterna, 78229
- Methodist Children's Hospital of South Texas
-
Temple, Texas, Förenta staterna, 76508
- Scott and White Memorial Hospital
-
-
Utah
-
Salt Lake City, Utah, Förenta staterna, 84113
- Primary Children's Hospital
-
-
Vermont
-
Berlin Corners, Vermont, Förenta staterna, 05602
- Central Vermont Medical Center/National Life Cancer Treatment
-
Burlington, Vermont, Förenta staterna, 05401
- University of Vermont Medical Center
-
Burlington, Vermont, Förenta staterna, 05405
- University of Vermont and State Agricultural College
-
-
Virginia
-
Falls Church, Virginia, Förenta staterna, 22042
- Inova Fairfax Hospital
-
Norfolk, Virginia, Förenta staterna, 23507
- Children's Hospital of The King's Daughters
-
Portsmouth, Virginia, Förenta staterna, 23708-2197
- Naval Medical Center - Portsmouth
-
Richmond, Virginia, Förenta staterna, 23298
- VCU Massey Comprehensive Cancer Center
-
Roanoke, Virginia, Förenta staterna, 24014
- Carilion Children's
-
-
Washington
-
Burien, Washington, Förenta staterna, 98166
- Saint Anne Hospital
-
Enumclaw, Washington, Förenta staterna, 98022
- Saint Elizabeth Hospital
-
Federal Way, Washington, Förenta staterna, 98003
- Saint Francis Hospital
-
Lakewood, Washington, Förenta staterna, 98499
- Saint Clare Hospital
-
Poulsbo, Washington, Förenta staterna, 98370
- Harrison HealthPartners Hematology and Oncology-Poulsbo
-
Seattle, Washington, Förenta staterna, 98105
- Seattle Children's Hospital
-
Silverdale, Washington, Förenta staterna, 98383
- Saint Joseph Medical Center Hematology and Oncology - Silverdale
-
Spokane, Washington, Förenta staterna, 99204
- Providence Sacred Heart Medical Center and Children's Hospital
-
Tacoma, Washington, Förenta staterna, 98405
- Mary Bridge Children's Hospital and Health Center
-
Tacoma, Washington, Förenta staterna, 98405
- Northwest Medical Specialties PLLC
-
Tacoma, Washington, Förenta staterna, 98431
- Madigan Army Medical Center
-
Tacoma, Washington, Förenta staterna, 98405
- Franciscan Research Center-Northwest Medical Plaza
-
-
West Virginia
-
Morgantown, West Virginia, Förenta staterna, 26506
- West Virginia University Healthcare
-
-
Wisconsin
-
Green Bay, Wisconsin, Förenta staterna, 54301
- Saint Vincent Hospital Cancer Center Green Bay
-
Marinette, Wisconsin, Förenta staterna, 54143
- Saint Vincent Hospital Cancer Center at Marinette
-
Marshfield, Wisconsin, Förenta staterna, 54449
- Marshfield Medical Center-Marshfield
-
Milwaukee, Wisconsin, Förenta staterna, 53226
- Children's Hospital of Wisconsin
-
-
-
-
-
Québec, Kanada, G1V 4G2
- CHU de Quebec-Centre Hospitalier de l'Universite Laval (CHUL)
-
-
Alberta
-
Calgary, Alberta, Kanada, T3B 6A8
- Alberta Children's Hospital
-
Edmonton, Alberta, Kanada, T6G 2B7
- University of Alberta Hospital
-
-
British Columbia
-
Vancouver, British Columbia, Kanada, V6H 3V4
- British Columbia Children's Hospital
-
-
Manitoba
-
Winnipeg, Manitoba, Kanada, R3E 0V9
- CancerCare Manitoba
-
-
Newfoundland and Labrador
-
St. John's, Newfoundland and Labrador, Kanada, A1B 3V6
- Janeway Child Health Centre
-
-
Nova Scotia
-
Halifax, Nova Scotia, Kanada, B3K 6R8
- IWK Health Centre
-
-
Ontario
-
Hamilton, Ontario, Kanada, L8N 3Z5
- McMaster Children's Hospital at Hamilton Health Sciences
-
Kingston, Ontario, Kanada, K7L 2V7
- Kingston Health Sciences Centre
-
London, Ontario, Kanada, N6A 5W9
- Children's Hospital
-
Ottawa, Ontario, Kanada, K1H 8L1
- Children's Hospital of Eastern Ontario
-
Toronto, Ontario, Kanada, M5G 1X8
- Hospital for Sick Children
-
-
Quebec
-
Montreal, Quebec, Kanada, H3H 1P3
- The Montreal Children's Hospital of the MUHC
-
Montreal, Quebec, Kanada, H3T 1C5
- Centre Hospitalier Universitaire Sainte-Justine
-
-
-
-
-
San Juan, Puerto Rico, 00926
- University Pediatric Hospital
-
San Juan, Puerto Rico, 00912
- San Jorge Children's Hospital
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
-
Patients with histologic diagnosis (by institutional pathologist) of newly diagnosed Ewing sarcoma or peripheral primitive neuroectodermal tumor (PNET) arising from bone or soft tissue and with metastatic disease involving lung, bone, bone marrow, or other metastatic site
-
For the purpose of this study metastatic disease is defined as one or more of the following:
-
Lesions which are discontinuous from the primary tumor, are not regional lymph nodes, and do not share a bone or body cavity with the primary tumor; skip lesions in the same bone as the primary tumor do not constitute metastatic disease; skip lesions in an adjacent bone are considered bone metastases; if there is any doubt whether lesions are metastatic, a biopsy of those lesions should be performed
-
Contralateral pleural effusion and/or contralateral pleural nodules
-
Distant lymph node involvement
-
Patients with pulmonary nodules are considered to have metastatic disease if the patient has:
- Solitary nodule >= 0.5 cm or multiple nodules of >= 0.3 cm unless lesion is biopsied and negative for tumor
- Patients with solitary nodule < 0.5 cm or multiple nodules < 0.3 cm are not considered to have lung metastasis unless biopsy documents tumor
-
Bone marrow metastatic disease is based on morphologic evidence of Ewing sarcoma based on hematoxylin and eosin (H&E) stains; in the absence of morphologic evidence of marrow involvement on H&E, patients with bone marrow involvement detected ONLY by flow cytometry, reverse-transcriptase (RT)-polymerase chain reaction (PCR), fluorescence in situ hybridization (FISH), or immunohistochemistry will NOT be considered to have clinical bone marrow involvement for the purposes of this study
- This study requires bilateral bone marrow biopsies at study entry; the suggested approach for patients with large pelvic tumors in which a posterior iliac crest bone marrow biopsy would track through the tumor is to instead undergo 2 marrow biopsies on the contralateral side (either 2 posterior biopsies or one posterior and one anterior biopsy)
-
Bone metastasis: This study utilizes whole body FDG-PET scans to screen patients for bone metastases; areas suspicious for bone metastasis based on FDG-PET scans require confirmatory anatomic imaging with either MRI or computed tomography (CT) (whole body FDG-PET/CT or FDG-PET/magnetic resonance [MR] scan acceptable); whole body technetium bone scans may be performed at the discretion of the investigator and are not required; for patients without other sites of metastatic disease whose sole metastatic site to qualify for study entry is a single area suspicious for bone metastasis identified by FDG-PET, confirmatory biopsy or anatomic imaging evidence of an associated soft tissue mass at that site is required for study entry
-
-
Patients must have adequate tumor tissue to meet the minimum requirement for submission
-
Enrolling institutions are reminded that submission of pre-treatment serum, tumor tissue and whole blood is required
-
Patients should only have had a biopsy of the primary tumor without an attempt at complete or partial resection; patients will still be eligible if excision was attempted or accomplished as long as adequate anatomic imaging (MRI for most primary tumor sites) was obtained prior to surgery
-
Creatinine clearance or radioisotope glomerular filtration rate (GFR) >= 70 mL/min/1.73 m^2 or a serum creatinine based on age/gender as follows (performed within 7 days prior to enrollment):
- Age < 6 months: Maximum serum creatinine (mg/dL): 0.4 for males and females
- Age 6 months to < 1 year: Maximum serum creatinine (mg/dL): 0.5 for males and females
- Age 1 to < 2 years: Maximum serum creatinine (mg/dL): 0.6 for males and females
- Age 2 to < 6 years: Maximum serum creatinine (mg/dL): 0.8 for males and females
- Age 6 to < 10 years: Maximum serum creatinine (mg/dL): 1 for males and females
- Age 10 to < 13 years: Maximum serum creatinine (mg/dL): 1.2 for males and females
- Age 13 to < 16 years: Maximum serum creatinine (mg/dL): 1.5 for males and 1.4 for females
- Age >= 16 years: Maximum serum creatinine (mg/dL): 1.7 for males and 1.4 for females
-
Total bilirubin =< 1.5 x upper limit of normal (ULN) for age (performed within 7 days prior to enrollment), and
-
Serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) < 3 x upper limit of normal (ULN) for age (performed within 7 days prior to enrollment) (except for patients with liver metastasis who may enroll if ALT < 5 times ULN for age)
-
Shortening fraction of >= 27% or
-
Ejection fraction of >= 50%
-
Patients must have a normal blood sugar level for age to participate; if an initial random draw (ie. non-fasting) blood glucose value is out of range, it is acceptable to repeat this test as a fasting draw
-
All patients and/or their parents or legal guardians must sign a written informed consent
-
All institutional, Food and Drug Administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met
Exclusion Criteria:
- Patients with regional node involvement as their only site of disease beyond the primary tumor will not be eligible
- Patients whose primary tumors arise in the intra-dural soft tissue (e.g. brain and spinal cord) are not eligible
- Patients who have received prior chemotherapy or radiation therapy are not eligible
- Female patients of childbearing potential are not eligible unless a negative pregnancy test result has been obtained; lactating females are not eligible unless they have agreed not to breastfeed their infants for the duration of protocol therapy; sexually active patients of reproductive potential are not eligible unless they have agreed to use an effective contraceptive method for the duration of protocol therapy
- Patients with known pre-existing diabetes mellitus will be excluded from study
- Patients receiving chronic pharmacologic doses of corticosteroids are not eligible; for the purposes of eligibility, chronic exposure is defined as anticipated exposure of > 3 weeks, including the sum of both pre-enrollment and anticipated post-enrollment dosing; patients on acute corticosteroid therapy (=< 3 weeks of total planned exposure) must still meet the normal blood glucose requirement; patients receiving chronic inhaled corticosteroids or chronic physiologic replacement doses of corticosteroids are eligible
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Regimen A (VDC/IE)
See Design Details. |
Given IV
Andra namn:
Given IV
Andra namn:
Given IV
Andra namn:
Given IV
Andra namn:
Given IV
Andra namn:
Given IV
Andra namn:
Given IV
Andra namn:
Undergo EBRT
Andra namn:
Given IV
Andra namn:
Undergo SBRT
Andra namn:
Undergo surgery |
|
Experimentell: Regimen B (VDC/IE + ganitumab)
INDUCTION THERAPY: Patients receive Induction therapy as in Regimen A and receive ganitumab IV over 30-60 minutes or 60-120 minutes on day 1 of weeks 1, 3, 5, 7, 9, and 11. LOCAL CONTROL THERAPY: Between weeks 13-18, patients undergo surgery and/or radiation therapy. CONSOLIDATION THERAPY: Patients receive Consolidation therapy as in Regimen A and receive ganitumab IV over 30-60 minutes or 60-120 minutes on day 1 of weeks 7, 9, 11, 13, and 15. METASTATIC SITE IRRADIATION: Patients with lung metastases undergo whole lung radiation and patients with bone metastases undergo definitive SBRT or EBRT. MAINTENANCE: Patients receive ganitumab IV over 30-60 minutes or 60-120 minutes every 3 weeks for 8 cycles. |
Given IV
Andra namn:
Given IV
Andra namn:
Given IV
Andra namn:
Given IV
Andra namn:
Given IV
Andra namn:
Given IV
Andra namn:
Given IV
Andra namn:
Undergo EBRT
Andra namn:
Given IV
Andra namn:
Undergo SBRT
Andra namn:
Undergo surgery Given IV
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Event-free Survival
Tidsram: 5 years after enrollment
|
Estimated 5-year EFS where EFS is calculated as the time from study enrollment to disease progression, disease relapse, occurrence of a second malignant neoplasm, death from any cause or last follow-up whichever occurs first. Kaplan-Meier method is used for estimation. Patients without an event are censored at last contact. |
5 years after enrollment
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Overall Survival
Tidsram: 5 years after enrollment
|
Time from study enrollment to death or last patient contact. |
5 years after enrollment
|
|
Frequency of Toxicity-events
Tidsram: Up to 202 days
|
The number of induction or consolidation reporting periods in which a CTC version 4 codeable grade 4 or greater non-hematological adverse event, grade 3 or greater left ventricular systolic dysfunction or the reporting period is terminated because of a CTC codeable event. |
Up to 202 days
|
Andra resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Serum IGF Pathway Component and Tissue Protein, Deoxyribonucleic Acid (DNA), and Ribonucleic Acid Markers
Tidsram: Up to 10 years
|
In addition to the log rank test the modeling approach will be used for the primary study comparison. Linear trend in EFS-risk will be investigated by segregating the marker level according to quartiles. For bone marrow response rate analyses, Fisher's exact test will be used to compare the objective bone marrow response rate (complete response vs. incomplete response) at start of local control between patients with biomarker levels above and below the group median. |
Up to 10 years
|
|
Tumor Cell Surface IGF-1R Expression
Tidsram: Up to 307 days
|
Extent of tumor cell IGF-1R co-expression will also be reported. Change in tumor cell IGF-1R co-expression in patients treated with and without ganitumab will be reported descriptively. |
Up to 307 days
|
|
Germline Polymorphisms in EGFR
Tidsram: Up to 10 years
|
EFS will be compared between patients with and without the presence of the minor allele using the log rank test, both for the entire patient population and for patients randomized to ganitumab. |
Up to 10 years
|
|
EWS Translocation
Tidsram: Up to 10 years
|
The institutional result of EWS tumor testing will be categorized as translocation detected (yes v. no) and the type of translocation detected will also be recorded. The proportion of patients with a particular EWS translocation variant will be tabulated. |
Up to 10 years
|
|
Circulating Tumor DNA (ctDNA) Testing
Tidsram: Up to 202 days
|
Will report the proportion of patients that have a change in translocation result associated with ctDNA testing across time periods. |
Up to 202 days
|
|
Serial Genomic Profiling
Tidsram: Up to 307 days
|
Will be identified by flow cytometry. Profiles will be presented graphically, and samples obtained from different sites of tumor within the same individual will also be presented. |
Up to 307 days
|
|
Occurrence of Sinusoidal Obstructive Disease (SOS) Associated With the Addition of Ganitumab to VDC/IE
Tidsram: Up to 202 days
|
The number of induction and maintenance cycles received by patients randomized to the experimental therapy where SOS is observed. Only patients who receive all reporting period therapy or experience SOS will contribute to this outcome measure. |
Up to 202 days
|
|
Frequency of Resolution of Bone Marrow Metastases
Tidsram: Up to 84 days
|
The number of patients who are enrolled with bone marrow metastases whose bone marrow disease is not detected after evaluation at the time of of first local control measure or the end of the Induction reporting period, whichever comes first. Only eligible patients who receive at least one dose of randomized treatment assignment will be considered for this measure. |
Up to 84 days
|
|
Frequency of Toxicity Events During Ganitumab Maintenance
Tidsram: Up to 307 days
|
The number of induction or consolidation reporting periods in which a CTC version 4 codeable non-hematological adverse event, grade 3 left ventricular systolic dysfunction or the reporting period is terminated because of a CTC codeable event. |
Up to 307 days
|
|
Trough Levels of Serum Ganitumab
Tidsram: Up to 15 days
|
Trough levels of serum ganitumab prior to the second dose of ganitumab during induction obtained will be categorized as less than 10 micrograms per milliliter or greater than or equal to 10 micrograms per milliliter. This analysis will be conducted for the first 10 eligible patients who receive ganitumab. |
Up to 15 days
|
|
Proportion of Patients Who Successfully Receive Planned Stereotactic Body Radiotherapy (SBRT)
Tidsram: 202 days
|
A patient who has SBRT planned for at least one metastatic site and receives successful SBRT treatment to at least 85% of metastatic sites in the treatment plan. Successful treatment is determined by IROC review criteria. Only eligible patients start the metastatic site radiation reporting period will be considered for this outcome measure. |
202 days
|
Samarbetspartners och utredare
Sponsor
Utredare
- Huvudutredare: Steven G DuBois, Children's Oncology Group
Publikationer och användbara länkar
Allmänna publikationer
- DuBois SG, Krailo MD, Glade-Bender J, Buxton A, Laack N, Randall RL, Chen HX, Seibel NL, Boron M, Terezakis S, Hill-Kayser C, Hayes A, Reid JM, Teot L, Rakheja D, Womer R, Arndt C, Lessnick SL, Crompton BD, Kolb EA, Daldrup-Link H, Eutsler E, Reed DR, Janeway KA, Gorlick RG. Randomized Phase III Trial of Ganitumab With Interval-Compressed Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma: A Report From the Children's Oncology Group. J Clin Oncol. 2023 Apr 10;41(11):2098-2107. doi: 10.1200/JCO.22.01815. Epub 2023 Jan 20.
- von Kruchten R, DelRocco NJ, Adams LC, Singh SB, Varniab ZS, Bender JG, Krailo MD, DuBois S, Daldrup-Link HE. Role of diffusion-weighted MRI in assessing Ewing sarcoma treatment response: Findings from a COG phase III trial. Magn Reson Imaging. 2026 Oct;132:110706. doi: 10.1016/j.mri.2026.110706. Epub 2026 May 27.
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Faktisk)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Beräknad)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
- Neoplasmer
- Neoplasmer efter histologisk typ
- Sarkom
- Neoplasmer, bindväv och mjukvävnad
- Osteosarkom
- Neoplasmer, benvävnad
- Neoplasmer, bindväv
- Sarkom, Ewing
- Organiska kemikalier
- Heterocykliska föreningar, 1-ring
- Heterocykliska föreningar
- Heterocykliska föreningar, 2-ring
- Heterocykliska föreningar, smältring
- Undersökningstekniker
- Terapeutik
- Kirurgiska ingrepp, operativ
- Kolväten
- Kolväten, cykliska
- Kolhydrater
- Fysiska fenomen
- Alkaloider
- Podofyllotoxin
- Tetrahydronaftaler
- Naftalar
- Polycykliska aromatiska kolväten
- Kolväten, aromatisk
- Polycykliska föreningar
- Glukosider
- Glykosider
- Förenad
- Organisationer
- Hälsovårdsekonomi och organisationer
- Fosforamidsen
- Kväve senapsföreningar
- Senapsföreningar
- Kolväten, halogenerad
- Fosforamider
- Organofosforföreningar
- Vinca alkaloider
- Secologanin tryptaminalkaloider
- Indolalkaloider
- Indolizidiner
- Indoliziner
- Anthracykliner
- Naftakener
- Aminoglykosider
- Strålbehandling
- Stereotaxiska tekniker
- Neurokirurgiska förfaranden
- Daunorubicin
- Oxaziner
- Cyklofosfamid
- Etoposid
- Doxorubicin
- Vincristine
- Ifosfamid
- Strålning
- Kongresser som ämne
- Strålkirurgi
- etoposidfosfat
- ganitumab
Andra studie-ID-nummer
- NCI-2014-02380
- U10CA180886 (U.S.S. NIH-anslag/kontrakt)
- U10CA098543 (U.S.S. NIH-anslag/kontrakt)
- NCI-2014-02380 (Registeridentifierare: CTRP (Clinical Trial Reporting Program))
- AEWS1221 (Annan identifierare: CTEP)
- s15-00442
- AEWS1221
- AEWS1221 (Annan identifierare: Children's Oncology Group)
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .